Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Breaking down fourth quarter of 2022 numbers, the Major Pharmaceutical Preparations company's had devastating revenue slide
SLS delivered fourth quarter of 2022 operating loss of $-9.446 million
Published Mar 21 2023
CSIMarket Team / CSIMarket.com
The revenue fell sharply by -92.662 % to $0.34 million from $4.67 million in the comparable financial reporting period a year ago and sequentially from $0.00 million.
For the fiscal time-frame ending December 31 2022 Sellas Life Sciences Group Inc realized net deficit of $-9.121 million, bigger than $-6.598 million a year ago.
the Major Pharmaceutical Preparations company announced deficit of $-41.30 million and revenue of $1.33 million in the financial year 2022.
Net deficit per share has widen to $-2.13 from $-1.34 in the preceding financial year, while by -88.86 % from $11.95 million a year ago.
Sellas Life Sciences Group Inc is expected to report next financial earnings on May 11, 2023.
Other SLS's news
SELLAS Boosts AML Treatment with Promising Phase 2a Data and FDA Fast Track Designation for SLS009
Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization
SELLAS Life Sciences Group, Inc. Announces Public Offering: An Opportunity for Shareholders
Sellas Life Sciences Group Inc Shows Improvement in 2023 First Quarter Results, But Concerns Remain
announced operating loss of $-7.146 millions, in the most recent fiscal period
The Diminishing Returns have expanded more at the amid the financial period closing March 31 2022
Other SLS's news
SELLAS Boosts AML Treatment with Promising Phase 2a Data and FDA Fast Track Designation for SLS009
Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization
SELLAS Life Sciences Group, Inc. Announces Public Offering: An Opportunity for Shareholders
Sellas Life Sciences Group Inc Shows Improvement in 2023 First Quarter Results, But Concerns Remain
announced operating loss of $-7.146 millions, in the most recent fiscal period
The Diminishing Returns have expanded more at the amid the financial period closing March 31 2022